Partnering in pediatrics
Alexion Pharmaceuticals Inc. is hoping that its research collaboration with Cincinnati Children's Hospital Medical Center will help the biotech build out a rare disease pipeline that currently is dominated by a single molecule-Soliris eculizumab. The deal is Alexion's first collaboration with a clinical center and complements its pipeline-building efforts with biotechs and academia.
For CCHMC, the deal brings the first infusion of corporate dollars into its two-year-old innovation fund.
Under the deal, Alexion will fund rare disease research programs at the hospital and will have an exclusive option to license completed programs. If Alexion exercises an option, it would be responsible for clinical development and commercialization, and the CCHMC would be eligible for milestones and royalties.
Further financial details were not disclosed, but Alexion established the Alexion Rare